© 2022 MJH Life Sciences and AJMC. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.
December 1st 2021
Bhavesh Shah, PharmD, and Robert Groves, MD, discuss the priorities payers should be taking into account when managing psoriasis treatment.
The panel details the clinical and economic burden when patients switch between agents in plaque psoriasis.
December 13th 2021
Dr Mark Lebwohl explains disease burden for patients with plaque psoriasis and discusses the common comorbidities clinicians see.
Bhavesh Shah, PharmD, and Mark Lebwohl, MD, explain the difficulties of patient adherence to psoriasis treatments.
December 15th 2021
Drs Lebwohl and Groves discuss patients with psoriasis and the increased risk they have for also being diagnosed with metabolic syndrome.
Bhavesh Shah, PharmD, and Mark Lebwohl, MD, elaborate on treatment effectiveness in patients with both psoriasis and metabolic syndrome.
December 21st 2021
Drs Groves and Lebwohl discuss payer considerations for ensuring treatment with the appropriate agent for patients with psoriasis and metabolic syndrome.
Mark Lebwohl, MD, details how he extrapolates clinical data in his decision-making when trying to treat patients with psoriasis.
January 4th 2022
Drs Lebwohl and Groves comment on what they factor in when deciding to switch agents and provide targeted treatments for psoriasis and metabolic syndrome.
Bhavesh Shaw, PharmD, elaborates on switching biologics in psoriasis treatment.